Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/23/2012CA2806616A1 Oligonucleotide chelate complexes
02/23/2012CA2805624A1 Compositions and methods for improved organ transplant preservation and acceptance
02/23/2012CA2804575A1 New compounds
02/23/2012CA2804333A1 Nalbuphine-based formulations and uses thereof
02/23/2012CA2803349A1 Composition pharmaceutique pour la prevention de l'hypotension arterielle peroperatoire chez l' etre humain
02/22/2012EP2420518A1 Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters
02/22/2012EP2420505A1 Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
02/22/2012EP2420503A1 Process for the synthesis of 14-oxygenated morphinan-6-ones
02/22/2012EP2420502A1 Fused pyrrolopyridine derivative
02/22/2012EP2420501A1 Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same
02/22/2012EP2420500A1 Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action
02/22/2012EP2420499A1 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors
02/22/2012EP2420498A1 5-substituted quinazolinone derivatives as anti-cancer agents
02/22/2012EP2420497A1 5-substituted quinazolinone derivatives as anti-cancer agents
02/22/2012EP2420496A2 Antiepileptic, hypocholesterolemic and neuroprotective compound
02/22/2012EP2420494A1 Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
02/22/2012EP2420491A1 3 , 5-substitued piperidine compounds as renin inhibitors
02/22/2012EP2420490A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
02/22/2012EP2420289A1 Composition of caffeic acid phenethyl ester (CAPE) and one of catechin, kaempherol and myricetin for potentiating antitumour effect and for treating tumours
02/22/2012EP2420241A1 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
02/22/2012EP2420240A1 Azithromycin for the treatment of nodular acne
02/22/2012EP2420239A2 Antiangiogenic agents
02/22/2012EP2420238A2 Anti-angiogenic agents
02/22/2012EP2420237A1 Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways
02/22/2012EP2420236A2 Anti-angiogenic agents
02/22/2012EP2420235A1 Methods and combination therapies for treating alzheimer's disease
02/22/2012EP2420234A1 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer
02/22/2012EP2420233A2 Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
02/22/2012EP2420232A2 Angiotensin II receptor antagonist for the prevention or treatment of cardiovascular diseases in cats
02/22/2012EP2420231A2 Angiotensin II receptor antagonist for the prevention or treatment of cardiovascular disease in cats
02/22/2012EP2420230A2 Antiangiogenic agents
02/22/2012EP2420229A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
02/22/2012EP2420228A1 Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
02/22/2012EP2420227A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
02/22/2012EP2420226A1 Pharmaceutical compositions of rifaximin
02/22/2012EP2420225A1 Methods and compositions for deterring abuse of opioid containing dosage forms
02/22/2012EP2420223A1 Aqueous pharmaceutical compositions containing borate-polyol complexes
02/22/2012EP2420147A1 Nutritional supplement compositon
02/22/2012EP2420146A1 Use of DPA(n-6) oils in infant formula
02/22/2012EP2419736A1 Methods of assessing activity of a polysaccharide composition
02/22/2012EP2419732A1 Prion-free nanoparticle compositions and methods
02/22/2012EP2419513A2 Regulation of aging by modulation of mitochondrial function
02/22/2012EP2419506A1 Bacterial strains having an outstanding ability to produce menaquinone
02/22/2012EP2419433A1 Hepatitis c virus inhibitors
02/22/2012EP2419432A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
02/22/2012EP2419431A1 Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof
02/22/2012EP2419429A1 Imidazopyrazines for use as kinase inhibitors
02/22/2012EP2419428A1 Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
02/22/2012EP2419427A1 Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use
02/22/2012EP2419426A1 ( pyrazol-3-yl) -1, 3, 4-thiadiazol-2-amine and ( pyrazol-3-yl) -1, 3, 4-thiazol-2-amine compounds
02/22/2012EP2419425A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
02/22/2012EP2419424A2 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
02/22/2012EP2419423A1 Fluoro substituted pyrimidine compounds as jak3 inhibitors
02/22/2012EP2419422A1 Imidazolidine-2,4-dione derivatives and use thereof as a medicament
02/22/2012EP2419421A1 Process for preparation of endothelial receptor antagonist (bosentan)
02/22/2012EP2419420A1 Indole derivative modulators of the alpha 7 nachr
02/22/2012EP2419419A1 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
02/22/2012EP2419418A1 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
02/22/2012EP2419417A1 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
02/22/2012EP2419415A1 Compounds affecting glycemic index
02/22/2012EP2419414A1 Protein phosphatase 2a-activating agents
02/22/2012EP2419412A1 Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
02/22/2012EP2419411A1 Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
02/22/2012EP2419410A1 Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
02/22/2012EP2419408A1 3-aryl or heteroaryl-substituted indole derivative
02/22/2012EP2419405A1 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
02/22/2012EP2419404A1 Anti-viral compounds
02/22/2012EP2419403A1 Vitamin d receptor agonists and uses thereof
02/22/2012EP2419402A1 Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
02/22/2012EP2419401A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
02/22/2012EP2419400A1 Monoamine reuptake inhibitors
02/22/2012EP2419399A1 Compositions and methods for the treatment of inflammation
02/22/2012EP2419398A1 A prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
02/22/2012EP2419176A1 Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis and/or pruritus
02/22/2012EP2419146A1 Modulation of inflammatory responses by factor xi
02/22/2012EP2419140A2 Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
02/22/2012EP2419139A2 Polymeric drug delivery systems and processes for producing such systems
02/22/2012EP2419138A1 Gel compositions for administration of pharmaceutically active compounds
02/22/2012EP2419136A2 Compositions and methods for treating cancer
02/22/2012EP2419135A1 Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
02/22/2012EP2419131A1 Macrocyclic lactone combination compositions, vaccines and methods for producing same
02/22/2012EP2419123A1 Novel post-translational fibrinogen variants
02/22/2012EP2419115A2 Composition for regulating the metabolism of lipids
02/22/2012EP2419111A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
02/22/2012EP2419110A1 Methods of treating cancers with her3 antisense oligonucleotides
02/22/2012EP2419109A1 Method for on-demand contraception using levonorgestrel or norgestrel
02/22/2012EP2419108A1 Method for on-demand contraception
02/22/2012EP2419107A1 Method and composition for treating macular degeneration
02/22/2012EP2419106A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
02/22/2012EP2419105A1 Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
02/22/2012EP2419104A2 5-ht4 receptor agonist compounds for treatment of cognitive disorders
02/22/2012EP2419103A1 Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
02/22/2012EP2419102A1 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
02/22/2012EP2419101A2 Method of treating disorders associated with protein kinase ck2 activity
02/22/2012EP2419100A2 Method of decreasing pro-adam10 secretase and/or beta secretase levels
02/22/2012EP2419099A2 Composition and use of n-alpha-methylhistamine
02/22/2012EP2419098A2 A medicinal cream made using miconazole nitrate and chitosan, and a process to make the same
02/22/2012EP2419097A1 Pharmaceutical compositions
02/22/2012EP2419096A2 Stabilization of radiopharmaceutical compositions using ascorbic acid
02/22/2012EP2419095A2 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
1 ... 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 ... 7860